Targets › DAO
1 program from 1 company in 3 trials: 3 Phase 2; Neurology, Infectious disease; next expected readout May 2027.
Catalyzes the oxidative deamination of D-amino acids with broad substrate specificity. Required to catabolize D-amino acids synthesized endogenously, of gastrointestinal bacterial origin or obtained from the diet, and to use these as nutrients (By similarity). (UniProt, P14920)
Open in Phaseline: the race on DAO, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Chang Gung Memorial Hospital | DAOIB plus AO NMDA-enhancing agent (DAO inhibitor) plus antioxidant | DAO | Phase 2 | Dementia; Alzheimer Disease; Long COVID | May 2027 |
Dementia (1) Alzheimer Disease (1) Long COVID (1)
small molecule (1)
Chang Gung Memorial Hospital (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.